丙肝重大进步!FDA批准吉利德全球泛基因型丙肝鸡尾酒Epclusa,治疗全部6种基因型丙肝

2016-06-29 佚名 生物谷

丙肝治疗领域的绝对霸主吉利德(Gilead)在研的一款泛基因型丙肝鸡尾酒疗法Epclusa近日在美国监管方面实现重大里程碑。FDA已批准Epclusa用于治疗全部6种基因型丙肝。此次批准,使Epclusa成为全球首个也是唯一一个全口服、泛基因型、单一片剂的丙肝治疗方案,该药同时也是吉利德开发的第3款基于sofosbuvir(索非布韦)的丙肝治疗药物。此外,Epclusa也是获批治疗基因型2和基因型

丙肝治疗领域的绝对霸主吉利德(Gilead)在研的一款泛基因型丙肝鸡尾酒疗法Epclusa近日在美国监管方面实现重大里程碑。FDA已批准Epclusa用于治疗全部6种基因型丙肝。此次批准,使Epclusa成为全球首个也是唯一一个全口服、泛基因型、单一片剂的丙肝治疗方案,该药同时也是吉利德开发的第3款基于sofosbuvir(索非布韦)的丙肝治疗药物。此外,Epclusa也是获批治疗基因型2和基因型3丙肝的首个单一片剂方案(不需要联合利巴韦林)。Epclusa的获批,标志着丙肝临床治疗的重大进步。之前,FDA已授予Epclusa的突破性药物资格和优先审查资格。

FDA批准的Epclusa治疗方案为:(1)Epclusa单药治疗12周,用于无肝硬化或伴有代偿期肝硬化(Child-Pugh A级)的丙肝患者;(2)Epclusa联合利巴韦林(RBV)治疗12周,用于伴有失代偿期肝硬化(Child-Pugh B或C级)的丙肝患者。

Epclusa(sof/vel,400mg/100mg)是一种日服一次的泛基因型丙肝鸡尾酒疗法,开发用于全部6种基因型(GT-1,-2,-3,-4,-5,-6)丙肝患者的治疗。该鸡尾酒由吉利德已上市的丙肝明星药Sovaldi(sofosbuvir)和另一种抗病毒药物velpatasvir组成。其中,sofosbuvir是一种核苷类似物聚合酶抑制剂,velpatasvir则是一种泛基因型NS5A抑制剂。

Epclusa(sof/vel)的获批,是基于4项III期ASTRAL临床研究的积极数据,这些研究在全部6种基因型(GT-1,-2,-3,-4,-5,-6)丙肝群体中评估了SOF/VEL的疗效和安全性。数据显示,该鸡尾酒疗法针对所有6种基因型丙肝全部有效,包括伴有代偿性和失代偿性肝硬化患者群体。4项研究中,1035例泛基因型丙肝患者用药12周后,治愈率达到了98%(SVR12,功能性治愈)。(备注:SVR12(完成治疗后12周的持续病毒学应答)定义为停止治疗12周后HCV RNA水平低于定量下限,表明患者的丙肝感染已经治愈,即功能性治愈。)

Epclusa将极大简化丙肝临床治疗,消除检测丙肝基因型必要性

Epclusa(sof/vel)作为首个由2种泛基因型、直接作用抗病毒药物(DAAs)组成的泛基因型丙肝鸡尾酒疗法,标志着丙肝临床治疗的重大进步。在美国,基因型1丙肝是最常见的丙肝类型;然而,在全球范围内,有一半以上的丙肝患者为其他基因型丙肝。目前,尽管丙肝的临床治疗已经成熟,但仍有许多患者亟需一种简易高效的泛基因型丙肝药物,尤其是极为难治的3型HCV患者。

Epclusa(sof/vel)作为首个泛基因型丙肝鸡尾酒疗法,将与吉利德当前的丙肝资产(Sovaldi和Harvoni)形成完美互补,将提供高的临床治愈率,同时有望简化丙肝的治疗,更为重要的是,将有望消除检测患者丙肝基因型的必要性。

业界预测:Epclusa(sof/vel)将成为史上最畅销的丙肝鸡尾酒疗法

目前,吉利德丙肝资产中有2种药物Sovaldi和Harvoni,这2个药物的空前成功,已帮助吉利德奠定丙肝治疗领域的绝对霸主地位。尽管竞争对手艾伯维在2014年底推出了另一款丙肝鸡尾酒疗法,但吉利德丙肝专营权仍继续控制着超过85%的市场份额。

Epclusa(sof/vel)是吉利德第3款以sofosbuvir为基础的丙肝鸡尾酒,业界对该药的商业前景非常看好,认为这款泛基因型丙肝鸡尾酒一旦上市,将成为吉利德丙肝资产中又一款重磅产品,并且很有可能成为史上最畅销的丙肝药物。

原始出处:

U.S. Food and Drug Administration Approves Gilead’s Epclusa? (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987791, encodeId=3cc9198e79188, content=<a href='/topic/show?id=ceb6685585' target=_blank style='color:#2F92EE;'>#Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6855, encryptionId=ceb6685585, topicName=Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Feb 16 08:30:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890812, encodeId=1f7218908124f, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Aug 28 09:30:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839454, encodeId=4f081839454e1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jul 13 03:30:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009003, encodeId=18a0200900335, content=<a href='/topic/show?id=66f364889c9' target=_blank style='color:#2F92EE;'>#泛基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64889, encryptionId=66f364889c9, topicName=泛基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Feb 01 13:30:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066208, encodeId=cc6c20662082b, content=<a href='/topic/show?id=14cc10295e33' target=_blank style='color:#2F92EE;'>#鸡尾酒Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102957, encryptionId=14cc10295e33, topicName=鸡尾酒Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Mar 17 05:30:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92535, encodeId=15bd9253584, content=哇塞,丙肝的范鸡尾酒, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 09:20:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574805, encodeId=dea315e480581, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Fri Jul 01 02:30:00 CST 2016, time=2016-07-01, status=1, ipAttribution=)]
    2017-02-16 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1987791, encodeId=3cc9198e79188, content=<a href='/topic/show?id=ceb6685585' target=_blank style='color:#2F92EE;'>#Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6855, encryptionId=ceb6685585, topicName=Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Feb 16 08:30:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890812, encodeId=1f7218908124f, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Aug 28 09:30:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839454, encodeId=4f081839454e1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jul 13 03:30:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009003, encodeId=18a0200900335, content=<a href='/topic/show?id=66f364889c9' target=_blank style='color:#2F92EE;'>#泛基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64889, encryptionId=66f364889c9, topicName=泛基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Feb 01 13:30:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066208, encodeId=cc6c20662082b, content=<a href='/topic/show?id=14cc10295e33' target=_blank style='color:#2F92EE;'>#鸡尾酒Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102957, encryptionId=14cc10295e33, topicName=鸡尾酒Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Mar 17 05:30:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92535, encodeId=15bd9253584, content=哇塞,丙肝的范鸡尾酒, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 09:20:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574805, encodeId=dea315e480581, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Fri Jul 01 02:30:00 CST 2016, time=2016-07-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1987791, encodeId=3cc9198e79188, content=<a href='/topic/show?id=ceb6685585' target=_blank style='color:#2F92EE;'>#Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6855, encryptionId=ceb6685585, topicName=Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Feb 16 08:30:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890812, encodeId=1f7218908124f, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Aug 28 09:30:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839454, encodeId=4f081839454e1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jul 13 03:30:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009003, encodeId=18a0200900335, content=<a href='/topic/show?id=66f364889c9' target=_blank style='color:#2F92EE;'>#泛基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64889, encryptionId=66f364889c9, topicName=泛基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Feb 01 13:30:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066208, encodeId=cc6c20662082b, content=<a href='/topic/show?id=14cc10295e33' target=_blank style='color:#2F92EE;'>#鸡尾酒Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102957, encryptionId=14cc10295e33, topicName=鸡尾酒Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Mar 17 05:30:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92535, encodeId=15bd9253584, content=哇塞,丙肝的范鸡尾酒, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 09:20:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574805, encodeId=dea315e480581, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Fri Jul 01 02:30:00 CST 2016, time=2016-07-01, status=1, ipAttribution=)]
    2016-07-13 bugit
  4. [GetPortalCommentsPageByObjectIdResponse(id=1987791, encodeId=3cc9198e79188, content=<a href='/topic/show?id=ceb6685585' target=_blank style='color:#2F92EE;'>#Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6855, encryptionId=ceb6685585, topicName=Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Feb 16 08:30:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890812, encodeId=1f7218908124f, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Aug 28 09:30:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839454, encodeId=4f081839454e1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jul 13 03:30:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009003, encodeId=18a0200900335, content=<a href='/topic/show?id=66f364889c9' target=_blank style='color:#2F92EE;'>#泛基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64889, encryptionId=66f364889c9, topicName=泛基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Feb 01 13:30:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066208, encodeId=cc6c20662082b, content=<a href='/topic/show?id=14cc10295e33' target=_blank style='color:#2F92EE;'>#鸡尾酒Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102957, encryptionId=14cc10295e33, topicName=鸡尾酒Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Mar 17 05:30:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92535, encodeId=15bd9253584, content=哇塞,丙肝的范鸡尾酒, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 09:20:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574805, encodeId=dea315e480581, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Fri Jul 01 02:30:00 CST 2016, time=2016-07-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1987791, encodeId=3cc9198e79188, content=<a href='/topic/show?id=ceb6685585' target=_blank style='color:#2F92EE;'>#Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6855, encryptionId=ceb6685585, topicName=Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Feb 16 08:30:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890812, encodeId=1f7218908124f, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Aug 28 09:30:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839454, encodeId=4f081839454e1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jul 13 03:30:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009003, encodeId=18a0200900335, content=<a href='/topic/show?id=66f364889c9' target=_blank style='color:#2F92EE;'>#泛基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64889, encryptionId=66f364889c9, topicName=泛基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Feb 01 13:30:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066208, encodeId=cc6c20662082b, content=<a href='/topic/show?id=14cc10295e33' target=_blank style='color:#2F92EE;'>#鸡尾酒Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102957, encryptionId=14cc10295e33, topicName=鸡尾酒Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Mar 17 05:30:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92535, encodeId=15bd9253584, content=哇塞,丙肝的范鸡尾酒, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 09:20:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574805, encodeId=dea315e480581, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Fri Jul 01 02:30:00 CST 2016, time=2016-07-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1987791, encodeId=3cc9198e79188, content=<a href='/topic/show?id=ceb6685585' target=_blank style='color:#2F92EE;'>#Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6855, encryptionId=ceb6685585, topicName=Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Feb 16 08:30:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890812, encodeId=1f7218908124f, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Aug 28 09:30:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839454, encodeId=4f081839454e1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jul 13 03:30:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009003, encodeId=18a0200900335, content=<a href='/topic/show?id=66f364889c9' target=_blank style='color:#2F92EE;'>#泛基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64889, encryptionId=66f364889c9, topicName=泛基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Feb 01 13:30:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066208, encodeId=cc6c20662082b, content=<a href='/topic/show?id=14cc10295e33' target=_blank style='color:#2F92EE;'>#鸡尾酒Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102957, encryptionId=14cc10295e33, topicName=鸡尾酒Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Mar 17 05:30:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92535, encodeId=15bd9253584, content=哇塞,丙肝的范鸡尾酒, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 09:20:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574805, encodeId=dea315e480581, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Fri Jul 01 02:30:00 CST 2016, time=2016-07-01, status=1, ipAttribution=)]
    2016-07-10 oo902

    哇塞,丙肝的范鸡尾酒

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1987791, encodeId=3cc9198e79188, content=<a href='/topic/show?id=ceb6685585' target=_blank style='color:#2F92EE;'>#Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6855, encryptionId=ceb6685585, topicName=Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Feb 16 08:30:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890812, encodeId=1f7218908124f, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Aug 28 09:30:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839454, encodeId=4f081839454e1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jul 13 03:30:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009003, encodeId=18a0200900335, content=<a href='/topic/show?id=66f364889c9' target=_blank style='color:#2F92EE;'>#泛基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64889, encryptionId=66f364889c9, topicName=泛基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Feb 01 13:30:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066208, encodeId=cc6c20662082b, content=<a href='/topic/show?id=14cc10295e33' target=_blank style='color:#2F92EE;'>#鸡尾酒Epclusa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102957, encryptionId=14cc10295e33, topicName=鸡尾酒Epclusa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Mar 17 05:30:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92535, encodeId=15bd9253584, content=哇塞,丙肝的范鸡尾酒, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 09:20:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574805, encodeId=dea315e480581, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Fri Jul 01 02:30:00 CST 2016, time=2016-07-01, status=1, ipAttribution=)]
    2016-07-01 qblt

相关资讯

吉利德泛基因型丙肝鸡尾酒疗法SOF/VEL获FDA优先审查资格,将极大简化丙肝临床治疗

丙肝巨头吉利德(Gilead)正在开发的一款泛基因型丙肝鸡尾酒疗法SOF/VEL(sofosbuvir/velpatasvir)近日在美国监管方面传来喜讯,FDA已授予该鸡尾酒疗法治疗全部6种基因型丙肝的优先审查资格,其审查周期将从常规的10个月缩短至6个月,有望使这款泛基因型丙肝鸡尾酒提前上市,造福美国广大丙肝群体。 SOF/VEL是一种日服一次的泛基因型丙肝鸡尾酒疗法,开发用于全部6种基因型

FDA批准吉利德Epclusa上市,又一抗丙肝霸主药物诞生?

美国FDA批准了吉利德科学的又一抗丙肝药物Epclusa上市,用于治疗成人慢性丙型肝炎病毒(HCV)感染。对于患有中度至重度肝硬化(失代偿性肝硬化)的患者,Epclusa须和利巴韦林联合使用。在3个共有1558位无肝硬化或者代偿期肝硬化(轻度肝硬化)患者参与的3期临床试验中,受试者连续12周每天口服一次Epclusa,治愈率达到95%至99%(SVR12=95-99%)。在一个有267位失代偿性肝

丙肝治疗药物专利因缺乏创新性和创造性步骤在印度遭拒

印度专利管理局驳回了吉利德公司治疗丙肝的药物的专利申请,此举受到仿制药支持者的欢迎,因为这是一种极大降低丙肝治疗成本的方式。过去一年,丙肝见证了极昂贵的药物的出现。印度专利管理局的决定表明如果专利申请没有充足的新颖性并缺乏创造性步骤,印度法律条款将禁止授予专利。 驳回裁定称,丙肝是流行病,影响了全世界1.7亿人口,印度就有1800万。其他来源显示的数据更高。 驳回裁定称医药获取及知识组织(I-MA

沙东战胜吉利德,赢取首轮丙肝药专利权大战

本月初,默沙东和吉利德卷入丙肝药的专利诉讼案,默沙东控告吉利德侵犯了两项专利权,并索赔30亿美元。如今这场官司第一轮已经结束,默沙东获胜。若陪审团判决成立,默沙东将有权向吉利德索要其重磅丙肝药Sovaldi和Harvoni的巨额专利费。 这一局官司的胜利对默沙东而言极为有利。最近默沙东丙肝药Zepatier获得FDA批准,这是继吉利德、艾伯维之后第三款上市的新型丙肝药,但是其预期销售额要远远低于

EMA正式受理吉利德三合一艾滋病新药上市申请

吉利德(Gilead)近日宣布,欧洲药品管理局(EMA)已正式受理三合一HIV复方单片R/F/TAF(利匹韦林/恩曲他滨/替诺福韦,25mg/200mg/25mg)的上市许可申请(MAA),这也标志着吉利德基于TAF开发的第3款产品进入监管审查阶段,另2种产品分别为二合一(F/TAF)和四合一(E/C/F/TAF)复方新药。除此之外,吉利德还在研发另一款四合一复方产品D/C/F/TAF。 R/F

吉利德HIV鸡尾酒疗法获FDA批准,年销售超10亿美元指日可待

吉利德公司HIV联合治疗方法得到FDA批准,这为吉利德公司在该治疗领域取得领袖地位奠定了一块基石。 此次获批的新药,名为Odefsey,是恩曲他滨(商品名Emtriva)、利匹韦林(强生公司,商品名为Edurant)、Tenofoviral afenamide(简写为TAF,是替诺福韦【商品名Viread】的加强版)的复方药物。这种药物获批治疗12岁及年龄更大患者的I型HIV病毒感染。I型H